High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non Hodgkin's lymphoma: A phase II study

British Journal of Cancer

Volumn 78, Issue 6, 1998, Pages 777-780

  Pronzato, P ^a   Lionetto, R ^b   Botto, F ^a   Pensa, F ^a   Tognoni, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Dose intensity; Granulocyte colony stimulating factor; Non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ONDANSETRON; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; FEVER; HAIR LOSS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

EID: 0031660077     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.578     Document Type: Article

References (30)

1. Ardizzoni A, Venturini M, Crino L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R and Van Zandwijk N (1993) High dose intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin etoposide and granulocyte-macrophage colony stimulating factor in the treatment of small cell lung cancer. Eur J Cancer 29A: 687-692
2. Ardizzoni A, Venturini M, Sertoli MR, Giannessi PG, Brema F, Danova M, Testore F, Mariani GL, Pennucci MC, Queirolo P, Silvestro S, Bruzzi P, Lionetto R, Latini F and Rosso R (1994) Granulocyte macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy. A randomised study in patients with advanced stage disease. Br J Cancer 69: 385-391
3. Brodsky RA, Bedi A and Jones RJ (1997) Are growth factors leukemogenic? Leukemia 10: 175-177
4. Coiffier B (1995) Fourteen years of high-dose CHOP (ACVB regiment): preliminary conclusions about the treatment the treatment of aggressive lymphoma patients. Ann Oncol 6: 211-177
5. Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Boccardo F, Brunetti I, Catsafados E, Chiara S, Foglia G, Gallo L, Iskra L, Mammoliti S, Parodi G. Ragni N, Rosso R, Rugiati S and Rubagotti A (1996) High dose versus low dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord Ovest. J Clin Oncol 14: 351-356
6. Cooper IA, Wolf MM, Robertson TI, Fox RM, Matthews JP, Stone JM, Chong Ding J. Dart G, Matthews J, Firkin FC, Raymond ML and Ironside P, for the Australian & New Zealand Lymphoma Group (1994) Randomized comparison of MACOP-B with CHOP in patients with intermediate grade non Hodgkin's lymphoma. J Clin Oncol 12: 769-778
7. De Cillis A, Anderson J, Bryant D, Wickermann DL and Fisher B (1997) Acute myeloid leukemia (AML) and myclodysplastic syndromes (MDS) on NSABP B-25: an update (abstract 459). Proc. Am Soc Clin Oncol 16: 130A
8. Fisher RI, De Vita VT Jr and Hubbar SM (1983) Diffuse aggressive lymphomas; increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98: 304-309
9. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA and Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006
10. Gordon LI, Andersen J, Habermann TM, Winter JN, Glick J, Schilder RJ and Cassileth P (1996) Phase I trial of dose escalation with Growth Factor support in patients with previously untreated diffuse aggressive lymphomas. Determination of the maximum tolerated dose of ProMACE-CytaBOM. J Clin Oncol 14: 1275-1281
11. Gurney H, Dodwell D, Thatcher N and Tattersal MHN (1993a) Escalating drug delivery in cancer chemotherapy: a review of concepts and practice part 1. Ann Oncol 4: 23-24
12. Gurney H, Dodwell D, Thatcher N and Tattersal MHN (1993b) Escalating drug delivery in cancer chemotherapy: a review of concepts and practice part 2. Ann Oncol 4: 103-115
13. Hryniuk W (1994) Randomized dial of escalated vs standard BACOP (bleomycin, adriamycin, cyclofosfamide, oncovin, prednisone) for intermediate grade lymphoma. Proc Am Soc Clin Oncol 10: 272
14. Hryniuk W and Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281-1288
15. Kehoe S, Poole CJ, Stanley A, Earl HM and Blachledge GRP (1994) A phase I/II trial of recombinant human granulocyte - macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. Br J Cancer 69: 537-540
16. Klimo P and Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Int Med 102: 596-602
17. Kwak LW, Halpern J, Olshen RA and Horng SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree structured survival analysis (1990). J Clin Oncol 8: 963-977
18. Lalisang RI, Wils JA, Nortier HW, Burghouts JT, Hupperets PS, Erakamp FL, Schouten HC, Blijham GH (1997) Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer. J Clin Oncol 15: 1367-1376
19. Lepage E, Gisselbrecht C, Haioun C, Sebban C, Hilly T, Bosly A, Morel P, Herbrecht R, Reyes F and Coiffier B. reporting for the GELA (1993) Prognostic significance of received dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann Oncol 4: 651-656
20. Longo DL, De Vita VT, Duffey PL (1991) Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 9: 25-38
21. Meyer RM, Hryniuk WM and Goodyear MDE (1991). The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 9: 339-347
22. Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
23. Mouridsen HT, Alfthan C, Bashtolt L, Bergh M, Dalmark S, Eksborg S, Hellsten S, Kjaer M, Peterson C, Skovsgard T, Sorensen JB, Trope C and Aabo K (1990). Current status of epirubicin (farmorubicin) in the treatment of solid tumors. Acta Oncol 29: 257-285
24. Pettengell R, Gurney H and Radford JA (1992) Dose limiting neutropenia in high grade non-Hodgkin's lymphoma: a randomised controlled trial of G-CSF. Blood 80: 1430-1436
25. Pronzato P, Campora E, Amoroso D, Bertelli G, Botto F, Conte PF, Setoli MR and Rosso R (1989) Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 12: 481-485
26. Pronzato P, Bertelli G, Vigani A and Vaira F (1996) A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer. Br J Cancer 73: 1425-1427
27. Pronzato P, Bertelli G, Bruna F, Tani F, Vaira F, Vanoli M and Vigani A (1997) Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced bladder cancer. Anticancer Res 17: 2325-2328
28. Shipp MA, Harrington DP and Klatt MM (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994
29. Shipp MA, Neuberg D, Janiceck M, Cancellos GP and Shulman LN (1995) High dose CHOP as initial therapy for patients with poor prognosis aggressive non-Hodgkin's lymphoma: a dose finding pilot study. J Clin Oncol 13: 2916-2923
30. Simon R (1989) Optimal two stage designs for phase II clinical trials. Controlled Clin Trials 10: 1-10